NAMs Adoption And Biopharma R&D Will Accelerate Market Expansion

Published
20 Apr 25
Updated
15 Aug 25
AnalystHighTarget's Fair Value
US$200.00
21.7% undervalued intrinsic discount
15 Aug
US$156.68
Loading
1Y
-22.4%
7D
5.3%

Author's Valuation

US$200.0

21.7% undervalued intrinsic discount

AnalystHighTarget Fair Value

Shared on07 May 25
Fair value Decreased 17%

Shared on30 Apr 25
Fair value Increased 20%

AnalystHighTarget made no meaningful changes to valuation assumptions.

Shared on23 Apr 25
Fair value Decreased 6.98%